Johnson & Johnson (JNJ) has been taken to court repeatedly over its talcum powder products, and last week a court ordered the company to pay $4.7 billion. It is likely that this ruling will get reversed, though, and it is unlikely that the majority of the other lawsuits will be decided against the company. The science and the FDA are on Johnson & Johnson's side, so this does not seem like a major long-term headwind.

Johnson & Johnson remains on growth track and looks attractively valued right here, investors also get a relatively high dividend yield of 2.9%.

READ FULL ARTICLE HERE